Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma

Abstract

'Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.', Urology., 65 (4).pp. 815-820.Further information on publisher's website:http://dx.doi.org/10. 1016/j.urology.2004.11.016 Publisher's copyright statement: NOTICE: this is the author's version of a work that was accepted for publication in Urology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be re ected in this document. Changes may have been made to this work since it was submitted for publication. A de nitive version was subsequently published in Urology, 65/4, 2005, 10.1016/j.urology.2004.11.016 Additional information: Use policyThe full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-pro t purposes provided that:• a full bibliographic reference is made to the original source • a link is made to the metadata record in DRO • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders.Please consult the full DRO policy for further details.

Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder

“…To address whether elevated CYP1A1 mRNA is reflective of CYP1A1 protein, immunohistochemical analyses of human bladder TCC TMAs were conducted, an approach previously shown with TCC to be highly representative of whole histologic sections (22,26). Expression of CYP1A1 was detected in all pathologic stages of TCC, with a correlation between increasing tumor stage and CYP1A1 expression (Supplementary Table S1.1).…”

“…CYP1A1 protein expression was assessed by immunohistochemistry in a TMA of human bladder TCC, as previously described (22). The specific protocol for CYP1A1 expression is shown in Supplementary Methods.…”

MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

“…This observation is in agreement with several published studies. MMP-1 and MMP-10 mRNA levels have been reported to be significantly higher in bladder cancers compared with normal urothelial tissues (43,44), and MMP-1 and pro-MMP-10 immunoreactivity is evidently stronger in tumor cells of both superficial and muscle-invasive bladder cancers (45,46). In addition, patients with bladder cancer with an increased urinary MMP-1 protein level are more likely to have an aggressive tumor of advanced stage and grade (47,48).…”

Application of MMP-7 and MMP-10 in Assisting the Diagnosis of Malignant Pleural Effusion

“…Previous studies have demonstrated that MMP-7 plays an important role in the metastases of endometrial, gastrointestinal carcinomas, colorectal cancer, and lung cancer (Shiomi et al, 2003;Safranek et al, 2009;Shi et al, 2010). It has been demonstrated that MMP-10 was overexpressed in several human tumors of epithelial origin, including gastric cancer, esophageal carcinoma, skin carcinoma, and bladder transitional cell carcinoma determined using the immunohistochemical staining or microarray techniques (Kerkela et al, 2001;Mathew et al, 2002;Seargent et al, 2005;Aung et al, 2006). There is no published study on the detection of MMP-7 and MMP-10 in PE.…”